162 related articles for article (PubMed ID: 37531736)
1. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.
Desai A; Rakshit S; Bansal R; Ashara Y; Potter A; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Schwecke A; Moffett N; Hocum C; Leventakos K; Adjei A; Marks R; Molina J; Mansfield AS; Chen ZM; Dimou A
Cancer Treat Res Commun; 2023; 36():100743. PubMed ID: 37531736
[TBL] [Abstract][Full Text] [Related]
2. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With
Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H
JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS
Chour A; Denis J; Mascaux C; Zysman M; Bigay-Game L; Swalduz A; Gounant V; Cortot A; Darrason M; Fallet V; Auclin E; Basse C; Tissot C; Decroisette C; Bombaron P; Giroux-Leprieur E; Odier L; Brosseau S; Creusot Q; Gueçamburu M; Meersseman C; Rochand A; Costantini A; Gaillard CM; Wasielewski E; Girard N; Cadranel J; Lafitte C; Lebossé F; Duruisseaux M
J Thorac Oncol; 2023 Oct; 18(10):1408-1415. PubMed ID: 37217096
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.
Ernst SM; Hofman MM; van der Horst TE; Paats MS; Heijboer FWJ; Aerts JGJV; Dumoulin DW; Cornelissen R; von der Thüsen JH; de Bruijn P; Hoop EO; Mathijssen RHJ; Koolen SLW; Dingemans AC
EBioMedicine; 2024 Apr; 102():105074. PubMed ID: 38507877
[TBL] [Abstract][Full Text] [Related]
5. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
6. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
Chour A; Basse C; Lebossé F; Bonte PE; Girard N; Duruisseaux M
Lung Cancer; 2024 May; 191():107789. PubMed ID: 38614068
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced
Thummalapalli R; Bernstein E; Herzberg B; Li BT; Iqbal A; Preeshagul I; Santini FC; Eng J; Ladanyi M; Yang SR; Shen R; Lito P; Riely GJ; Sabari JK; Arbour KC
JCO Precis Oncol; 2023 Jun; 7():e2300030. PubMed ID: 37384866
[TBL] [Abstract][Full Text] [Related]
8. Survival of patients with KRAS G12C mutated stage IV non-small cell lung cancer with and without brain metastases treated with immune checkpoint inhibitors.
Swart EM; Noordhof AL; Damhuis RAM; Kunst PWA; De Ruysscher DKM; Hendriks LEL; van Geffen WH; Aarts MJ
Lung Cancer; 2023 Aug; 182():107290. PubMed ID: 37419045
[TBL] [Abstract][Full Text] [Related]
9. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
Lee A
Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated
Dy GK; Govindan R; Velcheti V; Falchook GS; Italiano A; Wolf J; Sacher AG; Takahashi T; Ramalingam SS; Dooms C; Kim DW; Addeo A; Desai J; Schuler M; Tomasini P; Hong DS; Lito P; Tran Q; Jones S; Anderson A; Hindoyan A; Snyder W; Skoulidis F; Li BT
J Clin Oncol; 2023 Jun; 41(18):3311-3317. PubMed ID: 37098232
[No Abstract] [Full Text] [Related]
11. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
[TBL] [Abstract][Full Text] [Related]
12. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.
Passiglia F; Lucia Reale M; Lo Russo G; Pasello G; Minuti G; Bulotta A; Galetta D; Pelizzari G; Sini C; Bria E; Roca E; Pilotto S; Genova C; Metro G; Citarella F; Chiari R; Cortinovis D; Delmonte A; Russo A; Tiseo M; Cerea G; Carta A; Scotti V; Vavalà T; Brambilla M; Buffoni L; Buosi R; Catania C; Gori S; Grisanti S; Agustoni F; Garbo E; Malapelle U; Novello S
Lung Cancer; 2024 Jan; 187():107444. PubMed ID: 38157806
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
Nakajima EC; Drezner N; Li X; Mishra-Kalyani PS; Liu Y; Zhao H; Bi Y; Liu J; Rahman A; Wearne E; Ojofeitimi I; Hotaki LT; Spillman D; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Apr; 28(8):1482-1486. PubMed ID: 34903582
[TBL] [Abstract][Full Text] [Related]
14. Sotorasib in
Strickler JH; Satake H; George TJ; Yaeger R; Hollebecque A; Garrido-Laguna I; Schuler M; Burns TF; Coveler AL; Falchook GS; Vincent M; Sunakawa Y; Dahan L; Bajor D; Rha SY; Lemech C; Juric D; Rehn M; Ngarmchamnanrith G; Jafarinasabian P; Tran Q; Hong DS
N Engl J Med; 2023 Jan; 388(1):33-43. PubMed ID: 36546651
[TBL] [Abstract][Full Text] [Related]
15. Brief report on the efficacy of sotorasib in KRAS-Mutated NSCLC patients with brain metastases.
Lebouille-Veldman AB; Taros TN; Nawabi NLA; Mekary RA; Peng L; Phillips J
Lung Cancer; 2024 Jan; 187():107425. PubMed ID: 38061200
[TBL] [Abstract][Full Text] [Related]
16. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
17. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
18. Validation of an LC-MS/MS method for the determination of sotorasib, a KRAS
Wong P; Akrami A; Houk B; Vuu I; James CA
Bioanalysis; 2022 Oct; 14(19):1281-1292. PubMed ID: 36473022
[No Abstract] [Full Text] [Related]
19. Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.
Lin JJ; Chin E; Yeap BY; Ferris LA; Kamesan V; Lennes IT; Sequist LV; Heist RS; Mino-Kenudson M; Gainor JF; Shaw AT
J Thorac Oncol; 2019 Jan; 14(1):135-140. PubMed ID: 30205166
[TBL] [Abstract][Full Text] [Related]
20. [Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital].
Bessy C; Blin T; Pichon E; Marchand-Adam S; Carmier D
Rev Mal Respir; 2023 Jan; 40(1):17-23. PubMed ID: 36566134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
